Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
The theoretical thyroid cancer risk based on rodent studies has not materialized in human populations after over a decade of clinical use, though ongoing pharmacovigilance continues
#PharmaNews #HealthcareInnovation #PharmaStrategy #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ To view or add a comment, sign in Exploring the Complexities of GLP-1 Drugs GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro are revolutionizing diabetes and obesity treatment
PlexusDx is not affiliated with Medvi or Mochi Health and has no commercial relationship with the companies reviewed
However, the landmark SURMOUNT-5 trial (published in mid-2025), which compared the two medications head-to-head, clarified the clinical reality: Total Weight Loss: Tirzepatide drives significantly greater total weight loss (averaging over 20%) compared to semaglutide (averaging roughly 14%)
